This study evaluates urinary biomarkers and PSA to help determine the best approach to early detection of prostate cancer in patients with an elevated familial risk.
* Age 35-70 years
Capable of providing informed consent
Prognosis of > 5 years if affected by another cancer
Known PCa-related mutations: BRCA 1 and 2, Lynch syndrome, or p53
* Anuria
Prior diagnosis or treatment for PCa
Failure to provide informed consent
Life expectancy < 5 years
University of Michigan Rogel Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator